Information Provided By: 
Fly News Breaks for August 19, 2016
IART
Aug 19, 2016 | 05:33 EDT
After hosting investor meetings with management, Piper Jaffray analyst Matt O'Brien says that despite the 25% year-to-date rally in shares of Integra LifeSciences, investors have not missed it. There is "considerable revenue momentum" in the business, led by the DFU rollout and total ankle replacement, O'Brien tells investors in a research note. The analyst raised his price target for Integra shares to $94 from $86 and reiterates an Overweight rating on the name.
News For IART From the Last 2 Days
There are no results for your query IART
